HUTCHMED (China) (HMDCF) Long-Term Deferred Tax (2015 - 2025)
HUTCHMED (China)'s (HMDCF) quarterly Long-Term Deferred Tax came in at $12.7 million in Q4 2025, down 9.43% quarter-over-quarter from $14.0 million in Q4 2023.
Analysis
HUTCHMED (China) (HMDCF) Long-Term Deferred Tax (2015 - 2025) Analysis & Trends
HUTCHMED (China) (HMDCF) has reported Long-Term Deferred Tax for 10 consecutive years, with $12.7 million the latest figure, recorded in Q4 2025.
- On a quarterly basis, Long-Term Deferred Tax changed N/A year-over-year to $12.7 million in Q4 2025; TTM through Dec 2025 was $12.7 million, a N/A change from a year earlier, with the FY2025 full-year figure at $12.7 million, changed N/A from the prior year.
- Long-Term Deferred Tax was $12.7 million for Q4 2025 at HUTCHMED (China), down from $14.0 million in the prior quarter.
- Over five years, Long-Term Deferred Tax peaked at $14.0 million in Q4 2023 and troughed at $6.6 million in Q4 2021.
- A 4-year average of $11.5 million and a median of $12.7 million in 2022 frame the typical range for Long-Term Deferred Tax.
- Across the five-year window, Long-Term Deferred Tax jumped 338.02% in 2021 and increased 10.4% in 2023, its largest moves.
- Over 4 years, Long-Term Deferred Tax stood at $6.6 million in 2021, then jumped by 90.72% to $12.7 million in 2022, then increased by 10.4% to $14.0 million in 2023, then declined by 9.43% to $12.7 million in 2025.
- The last three Long-Term Deferred Tax figures came in at $12.7 million (Q4 2025), $14.0 million (Q4 2023), and $12.7 million (Q4 2022), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.50 Bn | 197.51 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 181.29 Bn | 178.11 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.55 Bn | 74.56 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.65 Bn | 56.47 Bn | 1.37 Bn |
| 6 | Moderna | 54.65 Bn | 49.52 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.18 Bn | 30.87 Bn | 992.69 Mn |
| 8 | Biogen | 31.36 Bn | 30.07 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.01 Bn | 30.01 Bn | 1.16 Mn |
| 10 | HUTCHMED (China) | 376.85 Mn | 391.04 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 12.66 Mn |
| Dec 31, 2023 | 13.97 Mn |
| Dec 31, 2022 | 12.66 Mn |
| Dec 31, 2021 | 6.64 Mn |
| Dec 31, 2020 | 1.52 Mn |
| Jun 30, 2020 | -2.39 Mn |
| Dec 31, 2019 | 815,000.00 |
| Dec 31, 2018 | 580,000.00 |
| Jun 30, 2018 | 681,000.00 |
| Dec 31, 2017 | 633,000.00 |
| Dec 31, 2016 | 372,000.00 |
| Jun 30, 2016 | 215,000.00 |
| Dec 31, 2015 | 250,000.00 |